Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:

HD201 (Herceptin Biosimilar)

HD204 (Avastin Biosimilar)

PBP1502 (Humira Biosimilar)

PBP’s current first in class antibody therapeutics portfolio includes:

PBP1510 Anti-PAUF Antibody for Pancreatic Cancer

PBP1710 Anti-CTHRC1 Antibody for Solid Tumors

The first biosimilar of PBP, HD201 Trastuzumab, has been filed and accepted for review with the EMA, projecting market launch in 2021. Prestige BioPharma´s next products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an innovative anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Manufacturing facilities for global commercial supply are located in Osong, South Korea.

DrugCategoryIndication
HD201Biosimilar, Trastuzumab (Herceptin)Breast Cancer, Gastric Cancer
HD204Biosimilar, Bevacizumab (Avastin)Solid Tumors
PBP1502Biosimilar, Adalimumab (Humira)Arthritis
PBP1510First In Class Antibody, UlenistamabPancreatic Cancer, Ovarian Cancer
PBP1601Biosimilar, Denosumab (Prolia)Bone Loss, Osteoporosis
PBP1602Biosimilar, Aflibercept (Eylea) Macular Edema, Metastatic Colorectal Cancer, Retinopathy
PBP1603Biosimilar, Eculizumab (Soliris)Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria
PBP1701Biosimilar, Ipilimumab (Yervoy)
Metastatic Melanoma, Unresectable Melanoma
PBP1710First In Class AntibodySolid Tumors
PBP1801Biosimilar, Pertuzumab (Perjeta)Breast Cancer
PBP2001Biosimilar, Ramucirumab (Cyramza)Metastatic/Gastric junction adenocarcinoma
PBP2002Biosimilar, Natalizumab (Tysabri)Active Crohn's disease
PBP2101Biosimilar, Nivolumab (Opdivo)Metastatic urothelial carcinoma
PBP2102Biosimilar, Pembrolizumab (Keytruda)Metastatic/Unresectable melanoma
IDC001First In Class Bispecific AntibodyPancreatic cancer, Ovarian cancer
IDC002First In Class Bispecific AntibodyPancreatic cancer, Ovarian cancer
IDC003First In Class Bispecific AntibodySolid tumors
IDC004First In Class Bispecific AntibodyPancreatic cancer, Ovarian cancer
IDC005First In Class Bispecific AntibodySolid tumors
IDC006First In Class Bispecific AntibodyBreast cancer, Metastatic gastric cancer
IDC007First In Class Bispecific AntibodyViral Infectious disease
IDC008First In Class Bispecific AntibodyPancreatic cancer, Ovarian cancer
IDC009First In Class Bispecific AntibodyPancreatic cancer, Ovarian cancer

Development Stage

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HD201 TRASTUZUMAB BIOSIMILAR
    INDICATION: BREAST CANCER, GASTRIC CANCER
  • HD204 BEVACIZUMAB BIOSIMILAR
    INDICATION: SOLID TUMORS
  • PBP1502 ADALIMUMAB BIOSIMILAR
    INDICATION: ARTHRITIS
  • PBP1510 First-In-Class ANTIBODY
    INDICATION: PANCREATIC CANCER
  • PBP1601 DENOSUMAB BIOSIMILAR
    INDICATION: BONE LOSS OSTEOPOROSIS
  • PBP1602 AFLIBERCEPT BIOSIMILAR
    INDICATION: MACULAR EDEMA, METASTATIC COLORECTAL CANCER, RETINOPATHY
  • PBP1603 ECULIZUMAB BIOSIMILAR
    INDICATION: ATYPICAL HAEMOLYTIC UREMIC SYNDROME, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
  • PBP1701 IPILIMUMAB BIOSIMILAR
    INDICATION: METASTATIC MELANOMA, UNRESECTABLE MELANOMA
  • PBP1710 First-In-Class ANTIBODY
    INDICATION: SOLID TUMORS
  • PBP1801 PERTUZUMAB BIOSIMILAR
    INDICATION: BREAST CANCERS
  • PBP2001 RAMUCIRUMAB BIOSIMILAR
    INDICATION: METASTATIC/GASTRIC JUNCTION ADENOCARCINOMA
  • PBP2002 NATALIZUMAB BIOSIMILAR
    INDICATION: ACTIVE CROHN'S DISEASE
  • PBP2101 NIVOLUMAB BIOSIMILAR
    INDICATION: METASTATIC UROTHELIAL CARCINOMA
  • PBP2102 PEMBROLIZUMAB BIOSIMILAR
    INDICATION: METASTATIC.UNRESECTABLE MELANOMA
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3